Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Adaptimmune Therapeutics (ADAP)

(Delayed Data from NSDQ)

$1.08 USD

+0.02 (1.42%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.08 +0.01 (0.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Adaptimmune Therapeutics PLC [ADAP]

Reports for Purchase

Showing records 101 - 120 ( 123 total )

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 101

01/14/2020

Pages: 4

Collaboration With Astellas Validates ADAP''s T-cell Development Expertise

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 102

01/13/2020

Pages: 4

Data That Are Hard To RECIST!

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 103

01/13/2020

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 104

11/18/2019

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 105

11/17/2019

Pages: 4

Updated Phase I Synovial Sarcoma Data Hint At Phase II Success

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 106

11/11/2019

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 107

11/11/2019

Pages: 5

Post-Infusion Biomarker Data Correlate With Responses in Synovial Sarcom

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 108

11/06/2019

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 109

11/06/2019

Pages: 5

The Marathon Continues With A Data-Driven Future

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 110

10/04/2019

Industry Report

Pages: 3

SITC Is Only 33 Days Away: Abstract Titles Released

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 111

10/01/2019

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 112

09/30/2019

Pages: 5

ESMO Update Increases Our Confidence on ADP-A2M4

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 113

08/01/2019

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 114

08/01/2019

Pages: 5

2Q19 Update - All Programs Moving Forward, More Updates At ESMO 2019

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 115

07/19/2019

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 116

07/18/2019

Pages: 5

SURPASSing The Solid Tumor Challenge With Next-Gen TCRs. Reiterate Buy.

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 117

06/28/2019

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 118

06/27/2019

Pages: 5

New CEO Adrian Rawcliffe to Lead Adaptimmune Towards Commercialization

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 119

06/24/2019

Pages: 10

When a Visit Gives You More. Reiterating Our Buy Rating and $7 PT.

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 120

06/24/2019

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party